Antigen Targeting Equipment & Supplies
43 equipment items found
Manufactured by:Ardigen based inKraków, POLAND
Quick solution for effective immune responses in clinical trials; We have created an Artificial Intelligence platform dedicated to being a part of the therapeutic cancer vaccine development. The ArdImmune Vax platform uses sequencing data to generate and prioritize antigen targets for cancer vaccines and T-cell ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
NK cells play a major role in the anti-tumor efficacy of certain tumor-antigen targeting antibodies. NK cells express CD16, an activating receptor that binds to the Fc portion of IgG antibodies. Once activated through CD16, NK cells are able to destroy antibody-coated target cells and secrete cytokines, such as interferon gamma, to recruit and ...
by:AdAlta Limited based inBundoora, AUSTRALIA
Under the Collaboration Agreement, AdAlta will discover and optimise panels of i-bodies that bind to designated solid tumour antigen targets, from which Carina will generate CAR-T cells and identify optimal CAR-T product candidates including bi-specific CAR-T products. Carina and AdAlta will jointly fund pre-clinical proof of concept studies in mouse tumour ...
Manufactured by:T-Cure BioScience, Inc. based inSherman Oaks, CALIFORNIA (USA)
Our exclusive iSORT (Isolation of Optimal Reverse Immunology Generated TCR) platform is able to isolate TCRs against unique selected tumor-associated intracellular and extracellular antigens and neoantigens in the context of an HLA molecule, allowing us to focus on specific cancers and patient populations based on their genetic makeups. Using this technology, we are able to ...
Manufactured by:TC BioPharm based inHolytown, UNITED KINGDOM
TCB004 is a gamma delta CAR-T product for the treatment of AML redirected against an undisclosed target antigen. The co-stim CAR structure on TCB004 prevents toxicity against healthy cells and is ideally suited for targeting AML where finding a target ubiquitously and exclusively presented on diseased cells has so far proved ...
Manufactured by:Beijing Meizheng Bio-Tech Co., Ltd based inYanqing District, CHINA
Purification of GST-tagged proteins can be performed under very mild conditions, which preserves the function and antigenicity of the target ...
Manufactured by:Vitrosens Biotechnology A.S. based inÜmraniye, TURKEY
Test kit serves the qualitative detection of H. pylori antigen in human fecal samples. ...
Manufactured by:INOVIO Pharmaceuticals based inPlymouth Meeting, PENNSYLVANIA (USA)
SynCon uses a proprietary computer algorithm that has been designed to identify and optimize the DNA sequence of the target antigen, whether it is a virus or a tumor. Once this sequence has been determined, the DNA is synthesized or reorganized, and manufacturing can ...
Manufactured by:InVivo BioTech Services GmbH a BRUKER Company based inHennigsdorf, GERMANY
At InVivo, your recombinant antibody production is in reliable hands. Recombinant antibodies for target screening, antigen production or drug discovery can be produced either by transient expression or from your own stable cell line in small to large scales. Transient expression is performed using our in house system InVEST. InVEST guarantees an approximately 80 ...
Manufactured by:TC BioPharm based inHolytown, UNITED KINGDOM
At TC BioPharm, we apply chimeric antigen receptor T cell (CAR-T) technology to gamma delta T (GDT) cells. This takes advantage of the endogenous gamma delta T cell receptor (TCR), and combines it with chimeric antigen receptors. This involves adding a transgene to the GDT cells which encodes for a truncated version of a conventional CAR, one which doesn’t contain a CD3ζ activating ...
by:DxDiscovery, Inc. based inReno, NEVADA (USA)
An essential aspect of immunoassay development is the identification of target antigens that are shed or secreted during infection that can be used as targets for diagnosis. In an attempt to identify circulating bacterial and fungal antigens that possess diagnostic potential, we developed a platform technology called “In ...
Manufactured by:Vitrosens Biotechnology A.S. based inÜmraniye, TURKEY
Test kit enables the qualitative determination of Rotavirus antigens in human fecal samples. It is an effective tool for the diagnosis of acute gastroenteritis resulting from a rotavirus infection. ...
Manufactured by:INOVIO Pharmaceuticals based inPlymouth Meeting, PENNSYLVANIA (USA)
INOVIO’s DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using one of INOVIO’s proprietary hand-held CELLECTRA smart devices. Once inside the cell, the DNA plasmids enable the cell to produce the targeted antigen. The antigen is processed naturally in the cell and triggers the desired T ...
Manufactured by:D-tek s.a. based inMons, BELGIUM
The M2 antibodies belong to the group of Anti-Mitochondrial Antibodies (AMA) and are strongly associated with PBC. At least 9 distinct AMA have been identified, which have been classified M1-M9 according to their antigen specificity and disease association. Of these, only the M2 subtype approaches absolute specificity for PBC. Indeed, about 95 % of PBC patients have M2 autoantibodies and, ...
Manufactured by:RapiGEN Inc. based inSuwon-si, SOUTH KOREA
It is the last enzyme of the glycolytic pathway, essential for ATP generation, and one of the most abundant enzymes expressed by P.falciparum. pLDH does not persist in the blood but clears about the same time as the parasites following successful treatment. The lack of antigen persistence after treatment makes the pLDH from P.vivax, P.ovale, or P.malariae exhibit 90-92% identity ...
Manufactured by:Elpiscience based inShanghai, CHINA
ES101 is a first-in-class tetravalent bispecific antibody targeting 4-1BB and PD-L1. It has a unique mechanism of action as 4-1BB activation is dependent on PD-L1 binding. 4-1BB is a T cell co-stimulatory receptor and is a compelling immune checkpoint target. 4-1BB targeting antibodies being developed by multinational companies have exhibited dose-dependent liver toxicity in clinical trials, ...
by:Hookipa Pharma Inc. based inVienna, AUSTRIA
Our scientific platform includes two distinct approaches to arenavirus-based therapies: replicating and non-replicating. Our replicating technology is designed to create a stronger immune response that we believe is more appropriate for use in oncology. Our non-replicating technology is designed to evoke a potent immune response for prophylactic use against infectious disease. ...
by:Taiwan Liposome Company, Ltd. (TLC) based inNangang Distric, TAIWAN
TLC is using antibodies and antibody fragments attached to lipid encapsulated drugs to develop more effective therapies in oncology. These antibody-linked nanomedicines actively target specific tissues using binding interactions between a specific antibody and a target antigen on the surface of a particular cell type. Compared with passively ...
Manufactured by:The Menarini Group based inFlorence, ITALY
MEN1309 is an antibody-drug conjugate (ADC) constituted by a fully human IgG1 antibody conjugated through a cleavable linker to a cytotoxic agent (a maytansin derivative, DM4), responsible for its antitumor activity. The target antigen, CD205, is highly expressed in a wide range of both solid and hematological cancer cells. Once MEN1309 binds its ...
by:Kephera Diagnostics, LLC based inFramingham, MASSACHUSETTS (USA)
Our proprietary assay technology is based on principles of particle interaction combined with a simple device, which together enable rapid detection of specific antibodies or antigens associated with the target pathogen. The broadly enabling technology is applicable to a wide range of disease targets and applications. Kephera’s expertise ...